Pharmaceutical Fiscal Accountability Act of 2002
Latest action · Jul 16, 2002 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 21, 2002
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Amends the Public Health Service Act to require the Director of the National Institutes of Health to support qualifying clinical research on the development of new drugs at designated small public or private entities. Emphasizes drug research which has the potential to make a significant contribution for the prevention, diagnosis, or treatment of a disease which has not received significant Federal funding. Entitles the Director to five percent of the profits from sales during the patent period.
Requires the Comptroller General to study and report to Congress on the effects of: (1) Federal funding on the costs of research and the pricing of prescription drugs; and (2) pharmaceutical patent extensions and market exclusivity periods on delays in introducing generic versions.
Cosponsors 1
Members who signed on, in the order they did. All signed on Jul 11, 2002.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NY | Major R. Owens | Jul 11, 2002 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jun 21, 2002 |
| Health Subcommittee | Referred Jul 16, 2002 |
Actions 3
Everything that happened, newest first.
- Jul 16, 2002Referred to the Subcommittee on Health.
- Jun 21, 2002Introduced in House
- Jun 21, 2002Referred to the House Committee on Energy and Commerce.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to allow certain applicants for approval of a generic drug to be eligible for a 180-day period of protection from competition, and for other purposes.
- Short Titles as Introduced
- Pharmaceutical Fiscal Accountability Act of 2002
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Clinical trials
- Commerce
- Congress
- Congressional investigations
- Congressional reporting requirements
- Corporate profits
- Drug approvals
- Drug industry
- Drugs
- Economics and Public Finance
- Federal aid to medical research
- Generic drugs
- Government Operations and Politics
- Health
- Intellectual property
- New products
- Patents
- Pharmaceutical research
- Prescription pricing
- Research and development
- Research and development contracts
- Research grants
- Restrictive trade practices
- Science, Technology, Communications
- Small business
Text 1
Each version as it was printed, newest first.
- Jun 21, 2002Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.